Revolution Medicines reported expanded ASCO data for daraxonrasib in second-line metastatic pancreatic cancer, highlighting a survival benefit in patients with KRAS/ RAS G12 mutations and in the all-comer population. The pivotal Phase 3 trial results were published alongside the presentation. Across the overall trial population, daraxonrasib extended median survival to 13.2 months versus 6.6 months for chemotherapy. Among patients with RAS G12 mutations, median survival was 13.2 months versus 6.6 months, with disease control measures also doubling compared with chemotherapy benchmarks. Investigators and outside experts characterized the dataset as practice-changing for a second-line setting where median outcomes have historically been well below one year, with ASCO noting improved pain and tumor marker trends soon after dosing.